C E M Griffiths
Overview
Explore the profile of C E M Griffiths including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
281
Citations
4922
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Iskandar I, Lunt M, Thorneloe R, Cordingley L, Griffiths C, Ashcroft D
Br J Dermatol
. 2021 Jun;
185(5):952-960.
PMID: 34128222
Background: Factors that might influence response to systemic treatment for moderate-to-severe psoriasis are varied, and generally, are poorly understood, aside from high bodyweight, suggesting that other unidentified factors may be...
12.
Reich K, Gordon K, Strober B, Armstrong A, Miller M, Shen Y, et al.
Br J Dermatol
. 2021 Jun;
185(6):1146-1159.
PMID: 34105767
Background: Psoriasis is a chronic disease requiring long-term therapy. Objectives: Physician- and patient-reported outcomes were evaluated through week 252 in VOYAGE 1 and VOYAGE 2. Methods: In total, 1829 patients...
13.
Lwin S, Snowden J, Griffiths C
Br J Dermatol
. 2021 May;
185(5):887-898.
PMID: 34036569
The management of moderate-to-severe psoriasis has been transformed by the introduction of biological therapies. These medicines, particularly those targeting interleukin (IL)-17 and IL-23p19, can offer clear or nearly clear skin...
14.
Dalal G, Wright S, Vass C, Davison N, Vander Stichele G, Smith C, et al.
Br J Dermatol
. 2021 May;
185(5):978-987.
PMID: 33991338
Background: New technologies have enabled the potential for stratified medicine in psoriasis. It is important to understand patients' preferences to enable the informed introduction of stratified medicine, which is likely...
15.
Al-Janabi A, Littlewood Z, Griffiths C, Hunter H, Chinoy H, Moriarty C, et al.
Br J Dermatol
. 2021 May;
185(3):646-648.
PMID: 33982284
No abstract available.
16.
17.
Lecaros C, Dunstan J, Villena F, Ashcroft D, Parisi R, Griffiths C, et al.
Clin Exp Dermatol
. 2021 Apr;
46(7):1262-1269.
PMID: 33914930
Background: Psoriasis is a serious and chronic noncommunicable disease. However, the fundamental measure of disease occurrence, the incidence, has been scarcely reported globally. There are no previous studies of psoriasis...
18.
Gottlieb A, Merola J, Reich K, Behrens F, Nash P, Griffiths C, et al.
Br J Dermatol
. 2021 Apr;
185(6):1124-1134.
PMID: 33913511
Background: Secukinumab [an interleukin (IL)-17A inhibitor] has demonstrated significantly higher efficacy vs. etanercept (a tumour necrosis factor inhibitor) and ustekinumab (an IL-12/23 inhibitor) in patients with moderate-to-severe plaque psoriasis. Objectives:...
19.
Mason K, Burden A, Barker J, Lunt M, Ali H, Kleyn C, et al.
J Eur Acad Dermatol Venereol
. 2021 Apr;
35(8):e496-e498.
PMID: 33866626
No abstract available.
20.